BRICS Interventional Cardiology Devices Market Outlook (2022-2033)

The market for interventional cardiology devices in the BRICS nations is projected to grow from US$ 3,373.0 million in 2024 to US$ 8,094.4 million by 2033, reflecting a compound annual growth rate (CAGR) of 10.2% from 2025 to 2033.

Executive Summary and Market Analysis

The BRICS countries are emerging as a significant growth area in the interventional cardiology devices sector, driven by their large populations, increasing incidence of cardiovascular diseases, and improved access to advanced medical treatments. China and India are at the forefront in terms of procedure volumes, bolstered by rapid advancements in healthcare infrastructure, urbanization, and heightened awareness of minimally invasive cardiac procedures.

In Brazil, there is a growing acceptance of interventional procedures in both public and private healthcare settings, while Russia is enhancing its capabilities in urban areas with a steady increase in coronary interventions. Despite ongoing challenges related to reimbursement and affordability, there is a consistent rise in demand for drug-eluting stents, diagnostic imaging equipment, and transcatheter heart valves. The BRICS nations are anticipated to play a crucial role in the global market's growth in the coming years.

Market Segmentation Analysis

The analysis of the interventional cardiology devices market is categorized by product type, material type, application, indication, and end user.

Product Type: The market is divided into coronary and peripheral stents, interventional catheters, PTCA balloons, guidewires and introducer sheaths, transcatheter heart valves, and others. The coronary and peripheral stents segment was the largest in 2024.
Material Type: This market is segmented into cobalt-chromium alloy, platinum-chromium alloy, nitinol, polymer, and others, with cobalt-chromium alloy leading in 2024.
Application: The market is split into therapeutic and diagnostic applications, with the therapeutic segment holding a larger market share in 2024.
Indication: The market is categorized into coronary artery disease, structural heart diseases, peripheral artery disease, and others, with coronary artery disease being the largest segment in 2024.
End User: The market is segmented into hospitals, ambulatory surgical centers, cardiac catheterization labs, and specialty clinics, with hospitals dominating the market in 2024.

Market Outlook

The interventional cardiology market in the BRICS nations is characterized by diversity and significant growth potential. While the maturity of each market varies—ranging from the rapid growth in China and India to the more established systems in Russia and Brazil—the overall region is witnessing a substantial increase in demand. This surge is primarily attributed to the rising prevalence of cardiovascular diseases among their large populations, driven by urbanization and lifestyle changes.

A major factor propelling this market is the increasing investment in healthcare infrastructure and rising health expenditures. As these economies develop, both public and private sectors are establishing and equipping modern hospitals with advanced catheterization labs. Additionally, a growing middle class with better access to health insurance and the financial means to afford modern treatments is significantly boosting the volume of interventional procedures and, consequently, the demand for devices such as stents and catheters.

Country Insights

The BRICS interventional cardiology devices market is segmented by country, including Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE, with China holding the largest market share in 2024.

China stands out as the most dynamic and largest market for interventional cardiology devices within the BRICS. The market is driven by a population exceeding 1.4 billion and a rapidly increasing prevalence of cardiovascular diseases, which are now the leading cause of mortality in the country. This situation creates a vast patient base requiring frequent interventions.

A significant factor contributing to this market's growth is the strong governmental support for domestic medical device manufacturing. Initiatives like the Made in China strategy have led to substantial investments in research and development and manufacturing capabilities for local companies such as Lepu Medical and MicroPort. This has intensified competition and reduced prices, making interventional devices more affordable and accessible across a broader range of hospitals, including those in rural areas. This push for domestic innovation, combined with a large patient population, positions China as a key player in the global market.

Company Profiles

Key players in the market include Medtronic, Boston Scientific Corporation, Abbott, B. Braun SE, TERUMO CORPORATION, Edwards Lifesciences Corporation, Teleflex Incorporated, Lepu Medical Technology (Beijing) Co., Ltd., W. L. Gore & Associates, Inc., and Meril Life Sciences. These companies employ strategies such as expansion, product innovation, and mergers and acquisitions to maintain competitiveness and provide innovative products to their customers. Show more